Swain, Nigel. A.; Batchelor, Dave; Beaudoin, Serge; Bechle, Bruce M.; Bradley, Paul A.; Brown, Alan D.; Brown, Bruce; Butcher, Ken J.; Butt, Richard P.; Chapman, Mark L.; Denton, Stephen; Ellis, David; Galan, Sebastien R. G.; Gaulier, Steven M.; Greener, Ben S.; de Groot, Marcel J.; Glossop, Mel S.; Gurrell, Ian K.; Hannam, Jo; Johnson, Matthew S.; Lin, Zhixin; Markworth, Christopher J.; Marron, Brian E.; Millan, David S.; Nakagawa, Shoko; Pike, Andy; Printzenhoff, David; Rawson, David J.; Ransley, Sarah J.; Reister, Steven M.; Sasaki, Kosuke; Storer, R. Ian; Stupple, Paul A.; West, Christopher W. published the artcile< Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7>, Electric Literature of 936250-20-3, the main research area is PF05089771 drug design synthesis NaV17 sodium channel inhibitor pain; diaryl ether aryl sulfonamide preparation sodium channel inhibitor pharmacokinetics.
A series of acidic diaryl ether heterocyclic sulfonamides that are potent and sub-type selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P 450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclin. in vitro properties. Concerns over non-metabolic routes of clearance, variable clearance in pre-clin. species and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clin. pharmacokinetics. The design strategies and results from pre-clin. PK and clin. human microdose PK data are described leading to the discovery of the first sub-type selective NaV1.7 inhibitor clin. candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.
Journal of Medicinal Chemistry published new progress about Analgesics. 936250-20-3 belongs to class pyrazoles-derivatives, and the molecular formula is C10H17BN2O2, Electric Literature of 936250-20-3.
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics